Study on Hypoglycemic and Cardiovascular Protective Effect of Metformin Combined with Dapagliflozin for Patients with Acute Chest Pains and Type 2 Diabetes
Objective To investigate the hypoglycemic and cardiovascular protective effect of dapagliflozin on the basis of metformin for patients with acute chest pains (in the paper,acute chest pain refers to chest pains caused by myocardial ischemia,hypoxia or necrosis) and type 2 diabetes (T2DM). Methods The paper chose 100 patients with type 2 diabetes combined with acute chest pains met research criteria in Boluo County People's Hospital from January 2022 to August 2023,treated with routine drugs,and divided them into the metformin+dapagliflozin group (the experimental group,n=50) and oral hypoglycemic drug group other than metformin+dapagliflozin (the reference group,n=50) randomly. Curative effect of each group was evaluated. Results After treatment,blood pressure,glycosylated hemoglobin,cardiac function,NT ProBNP and other indicators in the test experimental were better than the reference group (P＜0.05). Conclusion During treatment of patients with acute chest pains and type 2 diabetes,combination of metformin and dapagliflozin can reduce incidence of cardiovascular adverse events,regulate abnormal glucose and lipid metabolism of patients,which is conducive to cardiovascular protection.
Type 2 diabetesAcute chest painsDapagliflozinMetformin
万方数据
维普
